Identification of a Novel Bone Morphogenetic Protein-responsive Gene That May Function as a Noncoding RNA*

Kohsuke TakedaDagger , Hidenori IchijoDagger §, Makiko FujiiDagger , Yoshiyuki MochidaDagger §, Masao SaitohDagger §, Hideki NishitohDagger §, T. Kuber Sampathparallel , and Kohei MiyazonoDagger

From the Dagger  Department of Biochemistry, The Cancer Institute, Tokyo, Japanese Foundation for Cancer Research (JFCR), 1-37-1 Kami-Ikebukuro, Toshima-ku, Tokyo 170-8455, Japan and parallel  Creative Biomolecules, Inc., Hopkinton, Massachusetts 01748

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Bone morphogenetic proteins (BMPs)/osteogenic proteins (OPs), members of the transforming growth factor-beta superfamily, have a wide variety of effects on many cell types including osteoblasts and chondroblasts, and play critical roles in embryonic development. BMPs transduce their effects through binding to two different types of serine/threonine kinase receptors, type I and type II. Signaling by these receptors is mediated by the recently identified Smad proteins. Despite the rapid progress in understanding of the signaling mechanism downstream of BMP receptors, the target genes of BMPs are poorly understood in mammals. Here we identified a novel gene, termed BMP/OP-responsive gene (BORG), in C2C12 mouse myoblast cell line which trans-differentiates into osteoblastic cells in response to BMPs. Expression of BORG was dramatically induced in C2C12 cells by the treatment with BMP-2 or OP-1 within 2 h and peaked at 12-24 h, whereas transforming growth factor-beta had a minimal effect. BMP-dependent expression of BORG was also detected in other cell types which are known to respond to BMPs, suggesting that BORG is a common target gene of BMPs. Cloning and sequence analysis of BORG cDNA and the genomic clones revealed that, unexpectedly, the transcript of BORG lacks any extensive open reading frames and contains a cluster of multiple interspersed repetitive sequences in its middle part. The unusual structural features suggested that BORG may function as a noncoding RNA, although it is spliced and polyadenylated as authentic protein-coding mRNAs. Together with the observation that transfection of antisense oligonucleotides of BORG partially inhibited BMP-induced differentiation in C2C12 cells, it is possible that a new class of RNA molecules may have certain roles in the differentiation process induced by BMPs.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Bone morphogenetic proteins (BMPs)1/osteogenic proteins (OPs), members of the transforming growth factor-beta (TGF-beta ) superfamily, were originally identified by their activity to induce bone formation in vivo (1, 2). The BMP family includes various proteins, which can be divided into several subgroups based on their structural similarity; i.e. a group containing Drosophila decapentaplegic gene product, BMP-2, and BMP-4, a group containing Drosophila 60A gene product, OP-1/BMP-7, OP-2/BMP-8, BMP-5, and BMP-6/Vgr1, a group containing growth/differentiation factor-5, -6, and -7, and other members (3-5).

In vitro studies have revealed that BMPs have various biological effects on osteoblasts and chondroblasts, e.g. stimulation of proteoglycan synthesis in chondroblasts, and induction of collagen, alkaline phosphatase, and osteocalcin during chondrogenic and osteogenic differentiation (6-8). BMPs appear to exert various effects on many other cell types and play critical roles in embryonic development. For instance, null mutation in the BMP-2 gene leads to defects in amnion/chorion and cardiac development (9), and OP-1-deficient mice die shortly after birth because of poor kidney development and have eye defects and skeletal abnormalities (10, 11).

BMPs transduce their signals through binding to two different types of serine/threonine kinase receptors, type I and type II (12). Upon ligand binding followed by the formation of heteromeric receptor complexes, type I receptors are phosphorylated by type II receptors, and subsequent activation of the catalytic activity of type I receptor kinase is essential for signaling (13-16). Signaling by these receptors is mediated by the recently identified Smad proteins (17, 18). In the case of BMPs, phosphorylation of Smad1 (19-23) by the activated type I receptors allows association of Smad1 with Smad4 (24), and the complex moves into the nucleus, wherein Smads regulate the transcription of a subset of target genes. In Xenopus embryos, Smad5 is also able to mediate BMP signaling (25). In activin signaling, Smad2 interacts with the activin-response element of Mix.2, an immediate early activin-response gene, in concert with FAST-1, a novel member of the winged-helix family of putative transcription factor (26), whereas DNA-binding partners of Smad1 or Smad5 have yet been unknown in BMP signaling. Certain Smads have been shown to directly bind to DNAs (27, 28).

In order to elucidate how the Smad proteins and other transcription factors function in mediating BMP signals, and whether the signaling pathways not using the Smad proteins are also involved in BMP signaling, it is necessary to identify and analyze the genes directly induced by BMPs. A number of target genes of decapentaplegic gene product, the Drosophila counterpart of BMP-2, have been reported (18, 29). In Xenopus, homeobox-containing genes, Mix.1 (30), Xvent-1 (31, 32), Xvent-2 (33-35), and msx1 (36), and erythroid transcription factors, GATA-1 (37) and GATA-2 (38), have been shown to have immediate early response to BMPs. The mammalian counterparts of these genes may function as direct target genes of BMPs; however, little is known to date in mammals about the BMP-responsive genes except for TGF-beta -inducible early gene (TIEG), a putative zinc finger protein which is induced by BMP-2 as well as TGF-beta (39).

In the present study, we report the isolation of a novel gene, termed BMP/OP-responsive gene (BORG), of which expression was regulated by either BMP-2 or OP-1 in BMP-responsive cells. Interestingly, it lacks any extensive open reading frames (ORFs) and contains a cluster of multiple interspersed repetitive sequences in its middle part. A possibility that BORG may function as a noncoding RNA in the BMP-induced differentiation process is discussed.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cell Culture-- Mouse muscle myoblast C2C12 cells (40) and mouse embryo fibroblast C3H10T1/2 clone 8 were obtained from the American Type Culture Collection. ST2 mouse bone marrow stromal cells were obtained from the RIKEN Cell Bank (Tsukuba, Japan). C2C12 cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Nissui) containing 15% fetal bovine serum (FBS) and antibiotics (100 units/ml penicillin). When the C2C12 cells were treated with BMP-2, OP-1, or TGF-beta , medium was replaced by DMEM containing 5% FBS and antibiotics. C3H10T1/2 cells and ST2 cells were maintained in basal medium Eagle's with Earle's salts (Life Technologies, Inc.) and RPMI 1640 (Nissui), respectively, in the presence of 10% FBS and antibiotics.

RNA Isolation-- Total RNA was isolated from the cells by using Isogen (Wako), and poly(A)+ RNA was purified by binding to Oligotex-dT30 Super (Takara Biomedicals) as described by the manufacturer's instructions.

Differential Display-- C2C12 cells were cultured in DMEM containing 15% FBS to reach confluency; the serum was reduced to 5%, and the cells were allowed to grow in the presence or absence of 300 ng/ml OP-1 for additional 2 h. Poly(A)+ RNA was extracted from the cells, and subjected to digestion with DNase I (MessageClean kit, GenHunter) for 30 min at 37 °C to remove residual contaminated DNA fragments. Poly(A)+ RNA was further purified by phenol/chloroform extraction and precipitated with ethanol. The differential display method (41) was performed by using an RNAimage kit (GenHunter). Briefly, 0.2 µg of poly(A)+ RNA purified as above was reverse transcribed in a 20-µl reaction containing 25 mM Tris-HCl, pH 8.3, 37.6 mM KCl, 1.5 mM MgCl2, 5 mM dithiothreitol, 20 µM dNTPs, and 20 µM anchored oligo-dT primer, H-T11M (5'-AAGC(T11)(G/A/C)-3'), for 5 min at 65 °C and for 60 min at 37 °C, followed by 5 min at 75 °C. Murine Moloney leukemia virus reverse transcriptase (100 units) was added after 10 min incubation at 37 °C. PCR reaction was performed in a 20-µl reaction containing 10 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.5 mM MgCl2, 0.001% gelatin, 2 µM dNTPs, 0.2 µM arbitrary 13-mer (H-AP-1 to -80), 0.2 µM H-T11M, 2 µl of reverse transcription mixture, 1 µl of [alpha -35S]dATP (1200 Ci/mmol, Amersham), and 1 unit of Taq polymerase (Boehringer Mannheim). PCR conditions were 40 cycles of 94 °C (15 s), 40 °C (2 min), and 72 °C (30 s), followed by 5 min at 72 °C using a Perkin-Elmer 9600 thermocycler. The amplified products were separated on a 6% denaturing polyacrylamide gel. The gel was dried and exposed to an autoradiography film (Hyperfilm MP, Amersham). Differentially expressed products were cut out from the gel, extracted with H2O, and reamplified by the same set of primers under the same condition except for the use of 20 µM dNTPs. The secondary amplified products were separated side by side with the primary PCR products on a 6% denaturing polyacrylamide gel. The gel was dried and exposed to a film; the secondary amplified product was cut out from the gel, extracted with H2O, subcloned into pGEM-T vector (Promega), sequenced, and used as a probe for Northern blot analysis.

Northern Blot Analysis-- Two µg of poly(A)+ RNA was denatured, separated on a 1.2% agarose-formaldehyde gel, and blotted onto a nylon filter (Hybond-N, Amersham) with 20 × SSC (1 × SSC is 15 mM sodium citrate, 150 mM NaCl). Subcloned cDNA fragments from differential display and cDNAs for rat osteocalcin and glyceraldehydephosphate dehydrogenase (GAPDH) (gifts of Dr. S. Oida) were labeled with 32P by a Ready-To-Go DNA Labeling Kit (Pharmacia). Hybridization was performed at 43 °C overnight with labeled probe in 5 × SSPE (1 × SSPE is 180 mM NaCl, 10 mM Na2HPO4·7H2O, 1 mM EDTA), 50% formamide, 5 × Denhardt's solution, 0.5% SDS, 20 µg/ml salmon sperm DNA. The filters were washed twice in 2 × SSPE, 0.1% SDS at 43 °C for 15 min, once in 1 × SSPE, 0.1% SDS at 43 °C for 30 min, and once in 0.1 × SSPE, 0.1% SDS at room temperature for 15 min, followed by the analysis using a Fuji BAS 2000 Bio-Imaging Analyzer (Fuji Photo Film).

RT-PCR-- One µg of total RNA was reverse transcribed into single strand cDNA using Superscript Preamplification System (Life Technologies, Inc.) as described by the manufacturer's instructions. PCR was performed in a 50-µl reaction containing 1 × PCR reaction buffer (Boehringer Mannheim), 200 µM dNTPs, 0.2 µM B-S4 primer (5'-TAATGGGACAGCCTAGTAGG-3'), 0.2 µM B-AS4 primer (5'-TCCGTGTAAGAAAGCTGGCC-3'), 1 µl of single strand cDNA solution, and 2.5 units of Taq polymerase (Boehringer Mannheim). PCR conditions were 94 °C (5 min), 25 cycles of 94 °C (30 s), 55 °C (30 s), and 72 °C (30 s), followed by 10 min at 72 °C. A second round of PCR was performed with 2 µl of the first reaction as a template in the same reaction mixture except for the use of the internal primers, B-SN (5'-CAGCGGCCGCTAACTTGAGTATGTGG) and B-ASX1 (5'-CACTCGAGCTGACTATGATTTGTC-3') instead of B-S4 and B-AS4. The second PCR conditions were 94 °C (1 min), 15 cycles of 94 °C (30 s), 55 °C (30 s), and 72 °C (30 s), followed by 10 min at 72 °C. Specificity of the PCR products was confirmed by digestion with EcoRI and EcoRV. Primers for the mouse or rat GAPDH (CLONTECH) were also used as loading controls for the RT-PCR procedure.

5'-RACE-- Rapid amplification of cDNA ends (5'-RACE) was performed using a Marathon cDNA Amplification Kit (CLONTECH). Using 1 µg of poly(A)+ RNA isolated from OP-1-treated C2C12 cells, a library of adapter-ligated double strand cDNA was constructed as described by the manufacturer's instruction. For the initial attempt to obtain a full-length cDNA of BORG, two sequential antisense primers, B-AS1 (5'-ATCCAAGGTGAGGCCTAGTTCAC-3') and B-AS2 (5'-CAAGGTGGCCTCAGTGTGGATGC-3'), were designed from the sequence of the cDNA fragment obtained by the differential display. To isolate the 5'-end of BORG cDNA, B-AS6 (5'-ACGGCTGCTGGGATTTAAAC-3') and B-ASPE (5'-GTGGTAGCTGATCTTGATTGTCAAGCTTGTTGCCC-3') were designed from the sequence of the 5'-region of the mouse C2C12 cDNA library clone, clone P69 (see below). PCR reaction was performed in a 50-µl reaction containing 50 mM Tris-HCl, pH 9.2, 14 mM (NH4)2SO4, 1.75 mM MgCl2, 200 µM dNTPs, 0.2 µM B-AS1 primer, 0.2 µM adapter primer 1 (AP1, CLONTECH), 0.5 µl of adapter-ligated double strand cDNA solution, 2.5 units of Taq/Pwo DNA polymerase mixture (Expand Long Template PCR system, Boehringer Mannheim), and 0.3 µg of TaqStart Antibody (CLONTECH). PCR conditions were 94 °C (1 min), followed by 30 cycles of 94 °C (30 s) and 68 °C (4 min). A second round of PCR was performed with 0.5 µl of the first reaction as a template in the same reaction mixture except for the use of B-AS2 primer and nested adapter primer 2 (AP2, CLONTECH) instead of B-AS1 and AP1. The second PCR conditions were 94 °C (1 min), followed by 20 cycles of 94 °C (30 s) and 68 °C (4 min). The PCR product was subcloned into pGEM-T vector (Promega), sequenced, and used as a probe for cDNA library screening.

Preparation of cDNA Library and Isolation of cDNA Clones-- Using poly(A)+ RNA isolated from OP-1-treated C2C12 cells, an oligo(dT)-primed cDNA library with 1 × 106 independent clones was prepared by Uni-ZAP XR/Gigapack II Gold Cloning kit (Stratagene). The unamplified cDNA library was plated and lifted onto nylon filters (Hybond-N, Amersham), and immobilized by UV cross-linking. The duplicate filters were probed with the 32P-labeled 5'-RACE product at 65 °C overnight in the hybridization buffer containing 5 × SSPE, 5 × Denhardt's solution, 0.5% SDS, 20 µg/ml salmon sperm DNA. The filters were washed at 65 °C twice in 2 × SSPE, 0.1% SDS for 15 min, once in 1 × SSPE, 0.1% SDS for 30 min, and once in 0.1 × SSPE, 0.1% SDS for 15 min, followed by autoradiography. The positive clones were isolated and rescued into pBluescript SK(-). Nucleotide sequencing was performed on both strands.

Isolation of BORG Genomic Clones-- One million clones of a 129SV mouse genomic library (Stratagene) were screened with the full-length BORG cDNA as a probe as described above. Phage DNA was isolated from the positive clones and subjected to digestion with appropriate restriction enzymes to generate a physical map. The digested DNA was also probed with various portions of BORG cDNA to determine their location in the genome of BORG. Fragments that hybridized with the probes were subcloned into pBluescript SK(+) for nucleotide sequencing.

Antisense Oligonucleotides-- Antisense oligonucleotides at nucleotide positions from 902 to 921 of BORG cDNA (Fig. 5) were designed to hybridize to BORG RNA. Nucleotide sequences are: antisense, 5'-CCAGGCCACATACTCAAGTT-3'; sense, 5'-AACTTGAGTATGTGGCCTGG-3'. Both were synthesized as phosphorothionate oligonucleotides and high pressure liquid chromatography-purified by Greiner Japan (42). For transfection, 5 µM of each oligonucleotide was mixed with 2 µl/ml Tfx-50 (Promega) in DMEM containing 5% FBS, and added to C2C12 cells in the presence or absence of 300 ng/ml BMP-2. Total RNA extraction followed by RT-PCR for detecting the expression of BORG was done 6 h after the transfection as described above. Alkaline phosphatase activity was measured 36 h after the transfection as described previously (43).

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Identification of a Novel Target Gene of BMPs-- To identify a novel target gene of BMPs, we first examined the OP-1 responsiveness in a mouse myoblast cell line C2C12, which was reported to trans-differentiate into osteoblastic cells in response to BMP-2 (44). C2C12 cells were found to start to express osteocalcin mRNA (see below), as well as alkaline phosphatase activity (data not shown), representative markers for osteoblastic phenotype, by 24 h after the treatment with 300 ng/ml OP-1. In contrast, C2C12 cells not treated with OP-1 did not undergo such osteoblastic changes (data not shown), suggesting that C2C12 cells provide a useful system for the differential screening of OP-1-induced gene expression. We applied an mRNA differential display method (41) by using poly(A)+ RNA obtained from OP-1-treated or -untreated C2C12 cells. The C2C12 cells were maintained in DMEM containing 15% FBS. When the cells reached confluency, the serum was reduced, and the cells were allowed to grow in the presence or absence of 300 ng/ml OP-1 for an additional 2 h. Thereafter, poly(A)+ RNA was extracted, reverse transcribed into first strand cDNA and applied to the PCR-based differential screening using various combinations of arbitrary primers. Differentially expressed products (exemplified in Fig. 1A) which were observed only in the OP-1-treated material were cut out from the gel, reamplified by the same sets of the primers, and subcloned into plasmid vectors. DNA sequencing of the two differentially displayed clones as shown in Fig. 1A revealed that they encoded the same gene product with overlapping sequences. When one of the clones, named DD-10, was used as a probe for Northern blot analysis, a major transcript of approximately 3 kilobases was found to be increased in the OP-1-treated material (Fig. 1B), which confirmed that DD-10 corresponded to an OP-1-induced transcript in C2C12 cells. Together with the following induction data by BMP-2 (see below), the gene for this transcript was denoted BORG.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   Representative differential displays (A) and Northern blot analysis (B) of BORG. A, differential display was carried out using poly(A)+ RNA isolated from C2C12 cells untreated (-) or treated (+) with 300 ng/ml OP-1 for 2 h. 35S-Labeled PCR products were separated on a 6% denaturing polyacrylamide gel. Representative PCR products identified by using two different combinations of the primers are shown. The positive bands are marked by arrows. The differential display using the same set of the primers was performed three times with similar results. B, the differentially expressed product, clone DD-10, was labeled with 32P and used for Northern blot analysis of RNA from C2C12 cells untreated (-) or treated (+) with 300 ng/ml OP-1 for 2 h. The amount of mRNAs was verified by rehybridizing the filter with a GAPDH probe.

Expression of BORG-- A time course experiment by Northern blot analysis revealed that the expression of BORG was induced as early as 3 h after the addition of OP-1, peaked at 12-24 h, and decreased after 48 h (Figs. 2 and 3). While very weak expression of BORG was observed 3-12 h after the reduction of serum even without OP-1 (Fig. 2, OP-1(-) and Fig. 3, control), the extent of expression was much less compared with that observed in OP-1-treated cells. These results strongly suggested that OP-1 specifically induced BORG expression in C2C12 cells. When the same filter was reprobed with osteocalcin cDNA, osteocalcin mRNA was found to be induced 24-48 h after the treatment with OP-1 (Fig. 2), indicating that the expression of BORG precedes osteocalcin induction by OP-1 in C2C12 cells.


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 2.   Time course expression of BORG and osteocalcin mRNA in C2C12 cells. Confluent C2C12 cells were incubated with DMEM containing 5% FBS in the presence (+) or absence (-) of 300 ng/ml OP-1 for the indicated time. Poly(A)+ RNA (2 µg) extracted from the cells was subjected to Northern blot analysis using BORG PCR fragment clone DD-10 as a probe. The filter of OP-1-treated cells was rehybridized with the rat osteocalcin cDNA probe. The amount of mRNAs was verified by rehybridizing the filters with GAPDH probe.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of OP-1, BMP-2, and TGF-beta on expression of BORG RNA in C2C12 cells. Confluent C2C12 cells were incubated with DMEM containing 5% FBS in the absence (control) or presence of 300 ng/ml OP-1, 300 ng/ml BMP-2, or 25 ng/ml TGF-beta for the indicated time. Poly(A)+ RNA (2 µg) extracted from the cells was applied to Northern blot analysis using BORG PCR fragment clone DD-10 as a probe. The amount of mRNAs was verified by rehybridizing the filters with GAPDH probe (data not shown). Radioactive signals were quantitated on a Fuji BAS2000 Bio-Imaging Analyzer and plotted to give a graphical representation of the results. The amount of each transcript was calculated as relative activity against the background signal and normalized by RNA loading on the gels. Relative changes were calculated by standardizing the 0-h time point as a basal level.

To investigate the ability of other members of TGF-beta superfamily to induce BORG expression, we treated C2C12 cells with BMP-2 or TGF-beta . BORG was strongly induced by BMP-2 after 12-24 h and decreased after 48 h with a time course similar to OP-1 (Fig. 3). BORG was weakly induced in response to TGF-beta ; however, TGF-beta -induced expression of BORG peaked at 3 h after the treatment and decreased thereafter. Taking the fact into account that TGF-beta -induced expression of BORG was weak and transient, it is likely that BORG is a relatively specific target gene for OP-1 and BMP-2 but not TGF-beta .

To examine whether BMP-induced expression of BORG was a cell-type specific event in C2C12 cells, we tested the expression of BORG by RT-PCR in other cell lines that are known to respond to BMPs. In ST2 mouse bone marrow stromal cells (45) and C3H10T1/2 mouse embryo fibroblast (46), BORG was found to be induced within 1 h after the treatment with BMP-2 (Fig. 4), suggesting that BORG is a common target gene of BMPs in BMP-responsive cells.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 4.   Expression of BORG RNA in ST2 mouse bone marrow stromal cells and C3H10T1/2 mouse embryo fibroblast detected by RT-PCR. ST2 cells and C3H10T1/2 cells were treated with 300 ng/ml BMP-2 for the indicated time. Total RNA extracted from the cells was reverse transcribed into first strand cDNA, and subjected to RT-PCR analysis using BORG-specific primers. Primers for GAPDH were used as a loading control for the RT-PCR procedure.

cDNA Cloning of BORG-- To obtain a full-length cDNA for BORG, we applied 5'-RACE to poly(A)+ RNA isolated from OP-1-treated C2C12 cells by using two nested antisense primers designed from the sequence of the original PCR clone, DD-10. Specifically amplified products were subcloned into plasmid vectors, and two independent clones were sequenced. These clones encoded overlapping PCR products of 2,528 and 2,455 bp long, but a few nucleotides of these clones were different from each other in the overlapping region probably due to misincorporation of deoxynucleotides during the PCR procedure (data not shown).

Next, a cDNA library was constructed using poly(A)+ RNA isolated from OP-1-treated C2C12 cells and probed with the longer 5'-RACE product (2,528 bp). Several overlapping clones were obtained, and a clone, termed P69, yielded a 2,840-bp nucleotide sequence with a polyadenylation signal, AATAAA, followed by a poly(A) tail. The majority of the other clones were found to encode the partial sequence of P69. A few clones, whose inserts were longer than that of P69, appeared to encode premature transcripts since they contained additional intron-like sequences (data not shown).

To determine the 5'-end sequence of BORG RNA, we again applied 5'-RACE using two sequential antisense primers designed in the 5'-region of P69 and the cDNA templates used in the initial 5'-RACE. Sequencing of the specifically amplified products yielded an additional six nucleotides at the 5'-end of the cDNA. Thus, the combined nucleotide sequence of the 5'-RACE product and P69 was a putative full-length cDNA for BORG, containing a polyadenylation signal, AATAAA, at the 3'-end (nucleotide 2,812) (Fig. 5).


View larger version (125K):
[in this window]
[in a new window]
 
Fig. 5.   Nucleotide sequence of BORG cDNA. Bold face at the 5'-end indicates the nucleotide information obtained by 5'-RACE. The cluster of homologous regions to four types of interspersed repetitive sequences are shaded. Exon boundaries are indicated by arrowheads. A polyadenylation sequence is double-underlined at the 3'-end. The nucleotide sequence obtained by the initial differential display (clone DD-10) is boxed.

When a fragment (nucleotides 911-1,273) of BORG cDNA was used in Northern blot analysis as a probe, we detected OP-1-induced expression of the same sized transcript as that observed by using the original PCR clone, DD-10, as a probe (data not shown). These results indicate that the cDNA clone obtained from the OP-1-treated C2C12 cDNA library corresponded to a transcript of BORG.

Sequence Analysis of BORG-- A search of sequence data bases using the BLAST program (47) revealed an unexpected feature of BORG. Although no cDNA or mRNA sequence homologous to BORG transcript was detected in the data bases, mouse genomic sequence of origin region repeat-1a transposon-like element, clone origin region repeat-F (GenBank accession number: MMU17092) was highly homologous (76.7% identical) to a part of BORG cDNA (nucleotides 607-1,041), which indicates that BORG transcript contains an interspersed repetitive sequence (Fig. 5). To further investigate whether other interspersed repetitive sequences were involved in BORG cDNA sequence, we used RepeatMasker program2 that screens DNA sequences for interspersed repeats known to exist in mammalian genomes. BORG cDNA contained a cluster of homologous regions to four types of interspersed repetitive sequences in tandem; sequence of nucleotides 354-535 was homologous to type B4A of the short interspersed nucleotide element (SINE) (62.6% identical) (48), sequence of nucleotides 536-704 was homologous to the long terminal repeat region of origin region repeat-1B (70.2% identical), a member of a superfamily of mammalian apparent long terminal repeat-retrotransposons (49), sequence of nucleotides 709-1,042 was homologous to the internal sequence of origin region repeat-1A (78.7% identical), another member of mammalian apparent long terminal repeat-retrotransposons, and sequence of nucleotides 1,043-1,343 was homologous to RMER4 (62.6% identical), a long terminal repeat sequence that was not fully characterized in the RepeatMasker program or previous publications. These repetitive elements are frequently found within introns but much less in exons. Even if found in exons, they are usually found within 5'- or 3'-noncoding exons (50).

Another unexpected feature of BORG was the lack of any extensive ORFs in the cDNA sequence because of the high density of stop codons in all three reading frames (Fig. 6). The longest ATG-initiated ORF was found in nucleotides 911-1,273 (reading frame 2) which contained 363-bp long nucleotides with a favorable context for initiation of translation (51) with a purine at the -3 position (AGTATGT). However, this ORF (911-1,273) was preceded by 13 ATG codons, two of which occurred in strong contexts for initiation (nucleotides 670-676, GTCATGG and nucleotides 739-745, GTGATGG). Therefore, translation efficiency of the ORF (911-1,273) should be significantly reduced as reported by Kozak (51). In addition, the ORF (911-1,273) was completely included in the cluster of multiple interspersed repetitive sequences, and had no homology to any known coding sequences. Thus, the ORF (911-1,273) was unlikely to encode a protein. Four other ORFs longer than 100 bp were detected; two were in reading frame 1 (nucleotides 1, 111 to 1,344 and 1,687 to 1,905) and the other two were in reading frame 3 (nucleotides 1,602 to 1,739 and 2,412 to 2,543). However, none of them occurred in strong context for initiation. Taken together with the fact that these four ORFs were preceded by long 5'-noncoding regions including multiple ATG codons, these ORFs were also unlikely to function as coding sequences.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 6.   ORF analysis of BORG cDNA. The relative positions of all ATG codons and termination codons (TGA, TAA, and TAG) are indicated by open triangles and vertical lines, respectively, for each of the three reading frames.

To examine whether the BORG transcript encodes a protein, in vitro transcription and translation of the full-length cDNA for BORG was performed by using rabbit reticulocyte lysates. We could not detect any specific protein products from BORG cDNA (data not shown). Although it cannot be completely excluded that BORG may encode a small peptide, these results together with the unusual structural features of BORG cDNA strongly suggest that BORG transcript may act as a noncoding RNA.

Genomic Organization of BORG-- To negate a possibility that BORG is a processed pseudogene, we determined the genomic structure of BORG (Fig. 7). Using BORG cDNA as a probe, we isolated several overlapping genomic clones from a mouse genomic library. Detailed restriction mapping and Southern blot analyses of the clones and sequencing of their subclones revealed that BORG consisted of three exons interrupted by two introns. The sequences of the exon-intron boundaries were consistent with the donor/acceptor splicing rule, with GT at the donor site and AG at the acceptor site of the intron. Therefore, BORG transcripts, like authentic protein- coding mRNAs, are found to be both spliced and polyadenylated, excluding the possibility that BORG is a pseudogene.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 7.   Genomic structure of BORG. A, the linear map of the gene structure is shown. Three exons are indicated by shaded boxes. The location of restriction enzyme sites is shown with abbreviations: E, EcoRI; S, SacI. B, exon-intron boundaries of BORG. Exon and intron sequences are indicated by uppercase and lowercase letters, respectively. The approximate sizes of each intron are shown in parentheses. Conserved dinucleotides are indicated in boldface.

Effect of Antisense Oligonucleotides of BORG-- To investigate the roles of BORG in BMP-induced differentiation, we transfected C2C12 cells with antisense oligonucleotides of BORG and examined their effect on BORG expression and alkaline phosphatase activity induced by BMP-2. Transfection of antisense oligonucleotides of BORG decreased the extent of BMP-2-induced expression of BORG as determined by RT-PCR (Fig. 8), indicating the effectiveness of the antisense oligonucleotides on preventing the expression of BORG. As compared with sense oligonucleotides, transfection of antisense oligonucleotides partially inhibited alkaline phosphatase activity induced by BMP-2 (Fig. 8), suggesting the possible roles of BORG in BMP-induced osteoblastic differentiation in C2C12 cells.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of antisense oligonucleotides of BORG on BMP-2-induced expression of BORG and alkaline phosphatase activity. C2C12 cells were transfected with sense (S) or antisense (AS) oligonucleotides in the presence (+) or absence (-) of 300 ng/ml BMP-2. Total RNA was extracted from the cells 6 h after the transfection and applied to RT-PCR analysis using BORG specific primers (bottom panel). alkaline phosphatase activity was measured 36 h after the transfection as described previously (43) and shown as a graph. Values are shown as mean ± S.D. The experiments were repeated three times with similar results.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In the present study, we identified a novel gene, termed BORG, in a C2C12 mouse myoblast cell line by using an mRNA differential display method. C2C12 cells have been shown to differentiate into myotubes under reduced concentration of serum, but trans-differentiate into osteoblastic cells in the presence of BMP-2 (44). We found that OP-1 also induced the osteoblastic phenotype in C2C12 cells including the induction of osteocalcin mRNA (Fig. 2) and alkaline phosphatase activity (data not shown).

We demonstrated that expression of BORG was strongly induced by either BMP-2 or OP-1 in C2C12 cells, whereas TGF-beta , another member of TGF-beta superfamily, had a minimal effect. The induction of BORG was first detected 2-3 h after the treatment with BMP-2 or OP-1 and peaked after 12-24 h by Northern blot analysis in C2C12 cells (Figs. 1B, 2 and 3). Although the kinetics of BORG induction by BMP-2 were essentially identical to that by OP-1, BMP-2 had a slightly stronger activity in BORG induction as compared with OP-1, which correlated well with alkaline phosphatase and osteocalcin inducing activity by BMP-2 and OP-1 (data not shown). In contrast, TGF-beta , which does not induce an osteoblastic phenotype in C2C12 cells, induced BORG expression very weakly (Fig. 3). Moreover, the kinetics of BORG induction by TGF-beta , which peaked after 3 h and rapidly decreased after this, was clearly different from that by BMP-2 or OP-1. Supposing that BORG is a specific target gene for OP-1 and BMP-2 but not TGF-beta , BORG might also be sensitive to certain nonspecific stimulations such as TGF-beta , but only specific stimulations for osteoblastic differentiation such as BMP-2 and OP-1 may strongly increase and maintain its expression level for a longer period. BMP-2-dependent expression of BORG was also detected in two other cell types, ST2 and C3H10T1/2, both of which are known to respond to BMPs (45, 46), suggesting that BORG is a common target gene of BMPs.

In Xenopus, homeobox-containing genes, Mix.1 (30), Xvent-1 (31, 32), Xvent-2 (33-35), and msx1 (36), and erythroid transcription factors, GATA-1 (37) and GATA-2 (38), have been shown to be immediate early response genes of BMPs. The counterparts of these genes are likely candidates for immediate early response genes of BMPs in mammalian cells. Because of the rapid responsiveness of BORG to BMPs together with the fact that cycloheximide failed to inhibit the induction of BORG by OP-1 (data not shown), BORG may be classified as an immediate early response gene of BMPs. No such genes have been reported in mammalian cells to date, except for a putative zinc finger protein, called TGF-beta -inducible early gene (TIEG), which is induced by BMP-2 as well as TGF-beta (39). Therefore, detailed analysis of the regulatory mechanism of BORG expression will allow us to elucidate the precise molecular pathways involved in BMP signaling.

Sequencing analysis of BORG cDNA revealed several unexpected features of BORG cDNA. One of them is the existence of a cluster of multiple interspersed repetitive sequences in the middle part of the cDNA (Fig. 5). A large fraction of the mammalian genome is composed of interspersed repetitive sequences. Most numerous such sequences are the short and long interspersed nucleotide elements represented in the human genome by Alu and L1 sequences, respectively. Mammalian apparent long terminal repeat-retrotransposons form a class of repetitive elements distinct from SINEs and long interspersed nucleotides elements (49). The cluster of multiple interspersed repetitive sequences of BORG cDNA includes one region related to SINE and three regions related to mammalian apparent long terminal repeat-retrotransposons. The significance of the cluster of multiple interspersed repetitive sequences in BORG is unknown. The lack of any extensive ORFs is another feature of BORG. Because of the high density of stop codons in all three reading frames (Fig. 6), even the longest ATG-initiated ORF in BORG cDNA contained only 363 bp with poor contexts for coding a peptide. CTG or ACG also serves naturally as a start codon (51); however, the longest ORF was still the 399-bp CTG-initiated ORF started at nucleotide 875 with the upstream strong ATG codons, again suggesting that it is unlikely to encode a long peptide. These unusual structural features of the cDNA suggest that BORG encodes a noncoding RNA.

Recently, considerable attention has been attracted to two mammalian genes, H19 (52-54) and Xist (55-57), both of which function as untranslated RNAs. The structural features of the two genes resemble that of BORG in that they are spliced, polyadenylated, but have no extensive ORFs. H19 is implicated in imprinting of the insulin-2 and insulin-like growth factor 2 gene (53), and is demonstrated to have tumor-suppressor activity (54). Xist RNA acts in the nucleus and is essential for inactivation of most genes along the X chromosome in female (57). Thus, the characterization of these two RNA molecules supported a notion that untranslated RNAs can play important biological roles. In addition, although less characterized than H19 and Xist, three other noncoding RNAs have been reported to date. His-1, cloned from a common retroviral insertion site in murine leukemia virus-induced myeloid leukemia (58), and bic, cloned from a common retroviral insertion site in avian leukosis virus-induced B-cell lymphoma (59), may also encode noncoding RNAs, both implicated in growth control and oncogenesis. A novel synapse-associated noncoding RNA, 7H4, has been cloned as a candidate synaptic regulatory molecule from rat (60). The function of 7H4 in synaptic nuclei remains unknown, but interestingly, 7H4 cDNA has a short region containing homologous sequence to B1 SINE in the middle part of the cDNA, which is a structural feature in common with BORG. Therefore, BORG might be a new member of a growing unique class of noncoding RNAs. However, we should also consider a possibility that BORG may encode a small peptide. The gene product of a Drosophila heat shock gene, hsromega (61), which was suggested to act as a noncoding RNA molecule, was recently re-evaluated to encode a small peptide of 23-27 amino acids depending on the Drosophila species. In this case, it was suggested that the translation itself, rather than the generation of a functional protein product, may be important in order to monitor the state of translation activity of the cells. In either case, it is important to identify the functional region in the transcript of BORG. We are currently cloning the orthologs of mouse BORG in other species to identify conserved regions that may contribute to the function of BORG.

Although biological function of BORG remains largely unknown, observations that the induction of BORG by the treatment with BMPs preceded BMP-induced osteoblastic phenotype and that transfection of antisense oligonucleotides of BORG partially inhibited BMP-induced expression of alkaline phosphatase activity (Fig. 8) strongly reminds us of possible key roles of BORG in osteoblast differentiation. However, since we cannot exclude a possibility that the antisense oligonucleotides of BORG also inhibited other genes important for BMP-induced alkaline phosphatase activity, further experiments will be needed to disclose the functional roles of BORG in BMP-induced osteoblastic differentiation.

    ACKNOWLEDGEMENTS

We are grateful to M. Asashima, S. Takahashi, H. Okabayashi, and S. Noji for valuable discussion. We thank S. Oida for cDNAs for osteocalcin and GAPDH.

    FOOTNOTES

* This work was supported by grants-in-aid for scientific research from the Ministry of Education, Science, and Culture of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AB010885.

§ Present address: Dept. of Biomaterials Science, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8549, Japan.

To whom correspondence should be addressed: Dept. of Biomaterials Science, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8549, Japan. Tel.: 81-3-5803-5471; Fax: 81-3-5803-0192; E-mail: ichijo.det2{at}dent.tmd.ac.jp.

1 The abbreviations used are: BMP, bone morphogenetic protein; OP, osteogenic protein; BORG, BMP/OP-responsive gene; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; GAPDH, glyceraldehydephosphate dehydrogenase; RACE, rapid amplification of cDNA ends; SINE, short interspersed nucleotide element; TGF-beta , transforming growth factor-beta ; bp, base pair(s); ORF, open reading frame; PCR, polymerase chain reaction; RT, reverse transcriptase.

2 Smit, A. F. A., and Green, P., RepeatMasker, http://ftp.genome.washington; edu/RM/RepeatMasker.html.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Wozney, J. M., Rosen, V., Celeste, A. J., Mitsock, L. M., Whitters, M. J., Kriz, R. W., Hewick, R. M., and Wang, E. A. (1988) Science 242, 1528-1534[Medline] [Order article via Infotrieve]
  2. Özkaynak, E., Rueger, D. C., Drier, E. A., Corbett, C., Ridge, R. J., Sampath, T. K., and Oppermann, H. (1990) EMBO J. 9, 2085-2093[Abstract]
  3. Kingsley, D. M. (1994) Genes Dev. 8, 133-146[CrossRef][Medline] [Order article via Infotrieve]
  4. Reddi, A H. (1994) Curr. Opin. Genet. Dev. 4, 737-744[Medline] [Order article via Infotrieve]
  5. Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594[CrossRef][Medline] [Order article via Infotrieve]
  6. Wozney, J. M. (1992) Mol. Reprod. Dev. 32, 160-167[Medline] [Order article via Infotrieve]
  7. Yamaguchi, A., Katagiri, T., Ikeda, T., Wozney, J. M., Rosen, V., Wang, E. A., Kahn, A. J., Suda, T., and Yoshiki, S. (1991) J. Cell Biol. 113, 681-687[Abstract]
  8. Asahina, I., Sampath, T. K., and Hauschka, P. V. (1996) Exp. Cell Res. 222, 38-47[CrossRef][Medline] [Order article via Infotrieve]
  9. Zhang, H., and Bradley, A. (1996) Development 122, 2977-2986[Abstract/Free Full Text]
  10. Dudley, A. T., Lyons, K. M., and Robertson, E. J. (1995) Genes Dev. 9, 2795-2807[Abstract]
  11. Luo, G., Hofmann, C., Bronckers, A. L. J. J., Sohocki, M., Bradley, A., and Karsenty, G. (1995) Genes Dev. 9, 2808-2820[Abstract]
  12. Yamashita, H., ten Dijke, P., Heldin, C.-H., and Miyazono, K. (1996) Bone 19, 569-574[CrossRef][Medline] [Order article via Infotrieve]
  13. ten Dijke, P., Yamashita, H., Sampath, T. K., Reddi, A. H., Estevez, M., Riddle, D. L., Ichijo, H., Heldin, C.-H., and Miyazono, K. (1994) J. Biol. Chem. 269, 16985-16988[Abstract/Free Full Text]
  14. Koenig, B. B., Cook, J. S., Wolsing, D. H., Ting, J., Tiesman, J. P., Correa, P. E., Olson, C. A., Pecquet, A. L., Ventura, F., Grant, R. A., Chen, G.-X., Wrana, J. L., Massagué, J., and Rosenbaum, J. S. (1994) Mol. Cell. Biol. 14, 5961-5974[Abstract]
  15. Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., and Massagué, J. (1994) Nature 370, 341-347[CrossRef][Medline] [Order article via Infotrieve]
  16. Attisano, L., Wrana, J. L., Montalvo, E., and Massagué, J. (1996) Mol. Cell. Biol. 16, 1066-1073[Abstract]
  17. Massagué, J., Hata, A., and Liu, F. (1997) Trends Cell Biol. 7, 187-192[CrossRef]
  18. Heldin, C.-H., Miyazono, K., and ten Dijke, P. (1997) Nature 390, 465-471[CrossRef][Medline] [Order article via Infotrieve]
  19. Graff, J. M., Bansal, A., and Melton, D. A. (1996) Cell 85, 479-487[Medline] [Order article via Infotrieve]
  20. Hoodless, P. A., Haerry, T., Abdollah, S., Stapleton, M., O'Connor, M. B., Attisano, L., and Wrana, J. L. (1996) Cell 85, 489-500[Medline] [Order article via Infotrieve]
  21. Thomsen, G. H. (1996) Development 122, 2359-2366[Abstract/Free Full Text]
  22. Liu, F., Hata, A., Baker, J. C., Doody, J., Càrcamo, J., Harland, R. M., and Massagué, J. (1996) Nature 381, 620-623[CrossRef][Medline] [Order article via Infotrieve]
  23. Kretzschmar, M., Liu, F., Hata, A., Doody, J., and Massagué, J. (1997) Genes Dev. 11, 984-995[Abstract]
  24. Lagna, G., Hata, A., Hemmati-Brivanlou, A., and Massagué, J. (1996) Nature 383, 832-836[CrossRef][Medline] [Order article via Infotrieve]
  25. Suzuki, A., Chang, C., Yingling, J. M., Wang, X.-F., and Hemmati- Brivanlou, A. (1997) Dev. Biol. 184, 402-405[CrossRef][Medline] [Order article via Infotrieve]
  26. Chen, X., Rubock, M. J., and Whitman, M. (1996) Nature 383, 691-696[CrossRef][Medline] [Order article via Infotrieve]
  27. Yingling, J. M., Datto, M. B., Wong, C., Frederick, J. P., Liberati, N. T., and Wang, X.-F. (1997) Mol. Cell. Biol. 17, 7019-7028[Abstract]
  28. Kim, J., Johnson, K., Chen, H. J., Carroll, S., and Laughon, A. (1997) Nature 388, 304-308[CrossRef][Medline] [Order article via Infotrieve]
  29. Padgett, R. W., Savage, C., and Das, P. (1997) Cytokine Growth Factor Rev. 8, 1-9[CrossRef][Medline] [Order article via Infotrieve]
  30. Mead, P. E., Brivanlou, I. H., Kelley, C. M., and Zon, L. I. (1996) Nature 382, 357-360[CrossRef][Medline] [Order article via Infotrieve]
  31. Gawantka, V., Delius, H., Hirschfeld, K., Blumenstock, C., and Niehrs, C. (1995) EMBO J. 14, 6268-6279[Abstract]
  32. Ault, K. T., Dirksen, M.-L., and Jamrich, M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6415-6420[Abstract/Free Full Text]
  33. Onichtchouk, D., Gawantka, V., Dosch, R., Delius, H., Hirschfeld, K., Blumenstock, C., and Niehrs, C. (1996) Development 122, 3045-3053[Abstract/Free Full Text]
  34. Schmidt, J. E., von Dassow, G., and Kimelman, D. (1996) Development 122, 1711-1721[Abstract/Free Full Text]
  35. Ladher, R., Mohun, T. J., Smith, J. C., and Snape, A. M. (1996) Development 122, 2385-2394[Abstract/Free Full Text]
  36. Suzuki, A., Ueno, N., and Hemmati-Brivanlou, A. (1997) Development 124, 3037-3044[Abstract/Free Full Text]
  37. Xu, R.-H., Kim, J., Taira, M., Lin, J.-J., Zhang, C.-H., Sredni, D., Evans, T., and Kung, H.-F. (1997) Mol. Cell. Biol. 17, 436-443[Abstract]
  38. Maéno, M., Mead, P. E., Kelley, C., Xu, R. H., Kung, H. F., Suzuki, A., Ueno, N., and Zon, L. I. (1996) Blood 88, 1965-1972[Abstract/Free Full Text]
  39. Subramaniam, M., Harris, S. A., Oursler, M. J., Rasmussen, K., Riggs, B. L., and Spelsberg, T. C. (1995) Nucleic Acids Res. 23, 4907-4912[Abstract]
  40. Blau, H. M., Chiu, C.-P., and Webster, C. (1983) Cell 32, 1171-1180[Medline] [Order article via Infotrieve]
  41. Liang, P., and Pardee, A. B. (1992) Science 257, 967-971[Medline] [Order article via Infotrieve]
  42. Wagner, R. W. (1994) Nature 372, 333-335[CrossRef][Medline] [Order article via Infotrieve]
  43. Nishitoh, H., Ichijo, H., Kimura, M., Matsumoto, T., Makishima, F., Yamaguchi, A., Yamashita, H., Enomoto, S., and Miyazono, K. (1996) J. Biol. Chem. 271, 21345-21352[Abstract/Free Full Text]
  44. Katagiri, T., Yamaguchi, A., Komaki, M., Abe, E., Takahashi, N., Ikeda, T., Rosen, V., Wozney, J. M., Fujisawa-Sehara, A., and Suda, T. (1994) J. Cell Biol. 127, 1755-1766[Abstract]
  45. Yamaguchi, A., Ishizuya, T., Kintou, N., Wada, Y., Katagiri, T., Wozney, J. M., Rosen, V., and Yoshiki, S. (1996) Biochem. Biophys. Res. Commun. 220, 366-371[CrossRef][Medline] [Order article via Infotrieve]
  46. Katagiri, T., Yamaguchi, A., Ikeda, T., Yoshiki, S., Wozney, J. M., Rosen, V., Wang, E. A., Tanaka, H., Omura, S., and Suda, T. (1990) Biochem. Biophys. Res. Commun. 172, 295-299[Medline] [Order article via Infotrieve]
  47. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zang, Z., Miller, W., and Lipman, D. J. (1997) Nucleic Acids Res. 25, 3389-3402[Abstract/Free Full Text]
  48. Okada, N. (1991) Curr. Opin. Genet. Dev. 1, 498-504[Medline] [Order article via Infotrieve]
  49. Smit, A. F. A. (1993) Nucleic Acids Res. 21, 1863-1872[Abstract]
  50. Yulug, I. G., Yulug, A., and Fisher, E. M. C. (1995) Genomics 27, 544-548[CrossRef][Medline] [Order article via Infotrieve]
  51. Kozak, M. (1996) Mamm. Genome 7, 563-574[CrossRef][Medline] [Order article via Infotrieve]
  52. Brannan, C. I., Dees, E. C., Ingram, R. S., and Tilghman, S. M. (1990) Mol. Cell. Biol. 10, 28-36[Medline] [Order article via Infotrieve]
  53. Leighton, P. A., Ingram, R. S., Eggenschwiler, J., Efstratiadis, A., and Tilghman, S. M. (1995) Nature 375, 34-39[CrossRef][Medline] [Order article via Infotrieve]
  54. Hao, Y., Crenshaw, T., Moulton, T., Newcomb, E., and Tycko, B. (1993) Nature 365, 764-767[CrossRef][Medline] [Order article via Infotrieve]
  55. Brockdorff, N., Ashworth, A., Kay, G. F., McCabe, V. M., Norris, D. P., Cooper, P. J., Swift, S., and Rastan, S. (1992) Cell 71, 515-526[Medline] [Order article via Infotrieve]
  56. Brown, C. J., Hendrich, B. D., Rupert, J. L., Lafrenière, R. G., Xing, Y., Lawrence, J., and Willard, H. F. (1992) Cell 71, 527-542[Medline] [Order article via Infotrieve]
  57. Kuroda, M. I., and Meller, V. H. (1997) Cell 91, 9-11[CrossRef][Medline] [Order article via Infotrieve]
  58. Askew, D. S., Li, J., and Ihle, J. N. (1994) Mol. Cell. Biol. 14, 1743-1751[Abstract]
  59. Tam, W., Ben-Yehuda, D., and Hayward, W. S. (1997) Mol. Cell. Biol. 17, 1490-1502[Abstract]
  60. Velleca, M. A., Wallace, M. C., and Merlie, J. P. (1994) Mol. Cell. Biol. 14, 7095-7104[Abstract]
  61. Fini, M. E., Bendena, W. G., and Pardue, M. L. (1989) J. Cell Biol. 108, 2045-2057[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.